OCERA THERAPEUTICS, INC. (NASDAQ:OCRX) Files An 8-K Regulation FD Disclosure
Item 7.01. Other Events.
participate in investor meetings at the 35th Annual J.P. Morgan
Healthcare Conference beginning on Monday, January 9, 2017 in San
Francisco. A copy of the presentation slide deck to be used in
conjunction with the investor meetings is being furnished as
Exhibit 99.1 to this Report on Form 8-K.
hereto is intended to be furnished and shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
the results of its Phase 1 clinical study of orally-administered
OCR-002 in patients with cirrhosis. The full text of the press
release is filed as Exhibit 99.2 to this Current Report on Form
8-K and is incorporated herein by reference.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Ocera Therapeutics, Inc. Presentation Slide Deck.
|
|
|
99.2
|
Press release issued by Ocera Therapeutics, Inc. dated
January 5, 2017. |
About OCERA THERAPEUTICS, INC. > (NASDAQ:OCRX)
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge. OCERA THERAPEUTICS, INC. > (NASDAQ:OCRX) Recent Trading Information
OCERA THERAPEUTICS, INC. > (NASDAQ:OCRX) closed its last trading session up +0.05 at 2.20 with 516,922 shares trading hands.